MX2017006026A - Apilimod para uso en el tratamiento de cancer colorrectal. - Google Patents

Apilimod para uso en el tratamiento de cancer colorrectal.

Info

Publication number
MX2017006026A
MX2017006026A MX2017006026A MX2017006026A MX2017006026A MX 2017006026 A MX2017006026 A MX 2017006026A MX 2017006026 A MX2017006026 A MX 2017006026A MX 2017006026 A MX2017006026 A MX 2017006026A MX 2017006026 A MX2017006026 A MX 2017006026A
Authority
MX
Mexico
Prior art keywords
apilimod
colorectal cancer
treatment
methods
relates
Prior art date
Application number
MX2017006026A
Other languages
English (en)
Inventor
Beckett Paul
Lichenstein Henri
Xu Tian
Gayle Sophia
BEEHARRY Neil
LANDRETTE Sean
Conrad Chris
M Rothberg Jonathan
HERNANDEZ Marylens
Original Assignee
Lam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lam Therapeutics Inc filed Critical Lam Therapeutics Inc
Publication of MX2017006026A publication Critical patent/MX2017006026A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon

Abstract

La presente invención se refiere a métodos para tratar cáncer colorrectal con apilimod y composiciones y métodos relacionados.
MX2017006026A 2014-11-07 2015-11-06 Apilimod para uso en el tratamiento de cancer colorrectal. MX2017006026A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462077127P 2014-11-07 2014-11-07
US201562115228P 2015-02-12 2015-02-12
US201562119540P 2015-02-23 2015-02-23
PCT/US2015/059526 WO2016073884A1 (en) 2014-11-07 2015-11-06 Apilimod for use in the treatment of colorectal cancer

Publications (1)

Publication Number Publication Date
MX2017006026A true MX2017006026A (es) 2017-06-19

Family

ID=54548301

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006019A MX2017006019A (es) 2014-11-07 2015-11-06 Apilimod para uso en el tratamiento de melanoma.
MX2017006026A MX2017006026A (es) 2014-11-07 2015-11-06 Apilimod para uso en el tratamiento de cancer colorrectal.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017006019A MX2017006019A (es) 2014-11-07 2015-11-06 Apilimod para uso en el tratamiento de melanoma.

Country Status (16)

Country Link
US (2) US20190209576A1 (es)
EP (3) EP3215159B1 (es)
JP (2) JP6716585B2 (es)
KR (2) KR20170101907A (es)
CN (2) CN107206090A (es)
AU (2) AU2015342863B2 (es)
BR (2) BR112017009265A2 (es)
CA (2) CA2966356A1 (es)
ES (1) ES2734081T3 (es)
HU (1) HUE044153T2 (es)
IL (2) IL251904B (es)
MX (2) MX2017006019A (es)
PL (1) PL3215157T3 (es)
PT (1) PT3215157T (es)
RU (2) RU2731908C2 (es)
WO (2) WO2016073884A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016017112A2 (pt) 2014-01-24 2017-08-08 Ai Therapeutics Inc Composições de apilimod e métodos de uso das mesmas
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
EP3215158B1 (en) 2014-11-07 2019-05-08 AI Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
TW201726142A (zh) * 2016-01-21 2017-08-01 藍治療公司 用於以阿吡莫德治療癌症的生物標記
MX2019004179A (es) * 2016-10-12 2019-09-02 Ai Therapeutics Inc Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
EP3571200B8 (en) 2017-01-17 2022-08-03 HepaRegeniX GmbH Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN111801098A (zh) 2018-02-21 2020-10-20 人工智能治疗公司 使用阿匹莫德和谷氨酸能剂的组合疗法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693097B2 (en) * 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
JP4996261B2 (ja) 2004-02-06 2012-08-08 エラン ファーマシューティカルズ，インコーポレイテッド 腫瘍および転移性疾患を処置するための方法および組成物
TWI380816B (zh) * 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
EP1791544A4 (en) 2004-09-08 2007-09-12 Chelsea Therapeutics Inc DERIVATIVES OF QUINAZOLIN AS METABOLICALLY INERT ANTIFOLIC
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
US7863270B2 (en) 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
AU2006316605B2 (en) 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
WO2008008433A2 (en) 2006-07-12 2008-01-17 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
RU2438664C2 (ru) * 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
US8402515B2 (en) 2010-05-06 2013-03-19 Jonathan Weizman Apparatus and method for establishing a peer-to-peer communication session with a client device
WO2011146727A1 (en) * 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
BR112016017112A2 (pt) 2014-01-24 2017-08-08 Ai Therapeutics Inc Composições de apilimod e métodos de uso das mesmas
EP3215158B1 (en) * 2014-11-07 2019-05-08 AI Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
WO2016126707A1 (en) * 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
WO2016160102A1 (en) * 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法

Also Published As

Publication number Publication date
ES2734081T3 (es) 2019-12-04
US10765682B2 (en) 2020-09-08
BR112017009000A2 (pt) 2017-12-19
EP3215159A1 (en) 2017-09-13
RU2731908C2 (ru) 2020-09-09
CN107427522B (zh) 2021-06-15
EP3954375A1 (en) 2022-02-16
PL3215157T3 (pl) 2019-11-29
JP2017533963A (ja) 2017-11-16
IL251904B (en) 2021-03-25
AU2015342876B2 (en) 2020-07-09
EP3215159B1 (en) 2021-07-21
IL251903B (en) 2021-05-31
MX2017006019A (es) 2017-09-13
US20170333439A1 (en) 2017-11-23
JP2017535600A (ja) 2017-11-30
KR20170098813A (ko) 2017-08-30
WO2016073871A1 (en) 2016-05-12
AU2015342876A1 (en) 2017-06-15
CA2966334A1 (en) 2016-05-12
PT3215157T (pt) 2019-07-12
JP6716585B2 (ja) 2020-07-01
IL251903A0 (en) 2017-06-29
RU2017119066A (ru) 2018-12-07
EP3215157B8 (en) 2019-05-22
EP3215157B1 (en) 2019-04-10
CA2966356A1 (en) 2016-05-12
RU2017119064A3 (es) 2019-06-03
CN107427522A (zh) 2017-12-01
AU2015342863A1 (en) 2017-06-15
CN107206090A (zh) 2017-09-26
KR20170101907A (ko) 2017-09-06
HUE044153T2 (hu) 2019-09-30
US20190209576A1 (en) 2019-07-11
EP3215157A1 (en) 2017-09-13
RU2017119064A (ru) 2018-12-10
IL251904A0 (en) 2017-06-29
BR112017009265A2 (pt) 2017-12-19
WO2016073884A1 (en) 2016-05-12
RU2739992C2 (ru) 2020-12-30
RU2017119066A3 (es) 2019-06-07
JP6768682B2 (ja) 2020-10-14
AU2015342863B2 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
NZ731467A (en) Anti-tim3 antibodies and methods of use
SG11201700079VA (en) Combination therapy compositions and methods for treating cancers
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
IL253979A0 (en) Methods, preparations and kits for cancer treatment
MX370807B (es) Anticuerpos que se unen a axl.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
SI3200815T1 (sl) Postopki in sestavki za zdravljenje raka
IL276733A (en) Use of Aribolin in cancer treatment
ZA201900960B (en) Methods and compositions for the treatment of cancer
PH12016501422B1 (en) Functionalised benzopyran compounds and use thereof
ZA201808232B (en) Compositions and methods for the treatment of cancer
PH12016501838A1 (en) Compounds and their methods of use
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
EA201691907A1 (ru) Комбинированная терапия кураксинами
GB2546703A (en) Compounds
ZA201403006B (en) Composition for use in treatment of cancer
GB201410695D0 (en) Uses of oligouronates in cancer treatment